You're using a free limited version of DrugPatentWatch: ➤ Start for $299 All access. No Commitment.

Last Updated: December 30, 2025

CLINICAL TRIALS PROFILE FOR GLUMETINIB


✉ Email this page to a colleague

« Back to Dashboard


Clinical Trials for Glumetinib

Trial ID Title Status Sponsor Phase Summary
NCT03457532 ↗ A Phase I Study of SCC244 Recruiting Haihe Biopharma Co., Ltd. Phase 1 This is a Phase 1a/1b multi-center and open label study to evaluate the safety, tolorability, pharmacokinetics and priliminary efficacy of SCC244 in advanced solid tumors patients with c-MET alteration
NCT03457532 ↗ A Phase I Study of SCC244 Recruiting ShangHai HaiHe Pharmaceutical Phase 1 This is a Phase 1a/1b multi-center and open label study to evaluate the safety, tolorability, pharmacokinetics and priliminary efficacy of SCC244 in advanced solid tumors patients with c-MET alteration
NCT03466268 ↗ Study to Evaluate the Safety and Anti-tumor Activity of SCC244 Unknown status Haihe Biopharma Co., Ltd. Phase 1 This study evaluates the Safety, Tolerability, Pharmacokinetics, and Anti-tumor Activity of SCC244 in patients with advanced solid tumors with c-Met Alterations.
NCT03466268 ↗ Study to Evaluate the Safety and Anti-tumor Activity of SCC244 Unknown status ShangHai HaiHe Pharmaceutical Phase 1 This study evaluates the Safety, Tolerability, Pharmacokinetics, and Anti-tumor Activity of SCC244 in patients with advanced solid tumors with c-Met Alterations.
NCT04270591 ↗ Assessment of Anti-tumor and Safety in Glumetinib in Patients With c-MET-positive Non-Small Cell Lung Cancer Recruiting Haihe Biopharma Co., Ltd. Phase 1/Phase 2 Indication:Patients with Advanced c-MET-positive Non-Small Cell Lung Cancer Phase Ib (China only): Approximately 15 patients Phase Ⅱ (globally): Approximately 90 evaluable patients; addition of at least 6 patients in Safety Run-in (US only)
>Trial ID >Title >Status >Phase >Summary

Clinical Trial Conditions for Glumetinib

Condition Name

Condition Name
Intervention Trials
Advanced Solid Tumor 2
C-Met Exon 14 Mutation 1
Healthy Volunteers 1
Locally Advanced/Recurrent or Distant Metastasized Non-small Cell Lung Cancer With MET Overexpression 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH
Intervention Trials
Carcinoma, Non-Small-Cell Lung 3
Recurrence 2
Colorectal Neoplasms 1
Neoplasms 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for Glumetinib

Trials by Country

Trials by Country
Location Trials
China 27
United States 1
Japan 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State
Location Trials
Kentucky 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for Glumetinib

Clinical Trial Phase

Clinical Trial Phase
Clinical Trial Phase Trials
PHASE3 1
PHASE2 3
PHASE1 1
[disabled in preview] 5
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status
Clinical Trial Phase Trials
Recruiting 6
NOT_YET_RECRUITING 2
Unknown status 1
[disabled in preview] 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for Glumetinib

Sponsor Name

Sponsor Name
Sponsor Trials
Haihe Biopharma Co., Ltd. 5
ShangHai HaiHe Pharmaceutical 4
CSPC ZhongQi Pharmaceutical Technology Co., Ltd. 2
[disabled in preview] 3
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type
Sponsor Trials
Industry 13
OTHER 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.